Published On: Wed, Oct 19th, 2016

Recently Changed Price Targets On Lipocine Inc (LPCN)


A number of investment brokers have recently updated their price targets on shares of Lipocine Inc (LPCN).

Most recent broker ratings

10/11/2016 – Lipocine Inc had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 15 price target on the stock.

10/07/2016 – H.C. Wainwright began new coverage on Lipocine Inc giving the company a “buy” rating. They now have a USD 25 price target on the stock.

07/22/2015 – Roth Capital began new coverage on Lipocine Inc giving the company a “buy” rating. They now have a USD 36 price target on the stock.

07/16/2015 – Evercore ISI began new coverage on Lipocine Inc giving the company a “buy” rating. They now have a USD 18 price target on the stock.

01/09/2014 – Ladenburg Thalmann began new coverage on Lipocine Inc giving the company a “buy” rating. They now have a USD 25 price target on the stock.

The share price of Lipocine Inc (LPCN) was down -1.37% during the last trading session, with a day high of 3.84. 562110 shares were traded on Lipocine Inc’s last session.

The stock’s 50 day moving average is 3.95 and its 200 day moving average is 6.18. The stock’s market capitalization is 65.73M. Lipocine Inc has a 52-week low of 2.51 and a 52-week high of 14.80.

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.